Adaptimmune Therapeutics has a one year low of $0.51 and a one year high of $2.05. The business’s 50 day simple moving average is $0.59 and its 200-day simple moving average is $0.77. Get ...

Helen Tayton-Martin, Ph.D., M.B.A, Adaptimmune Co-Founder and Chief Business & Strategy Officer, will step down from the Company March 31, 2025 Gavin Wood, Chief Financial Officer, will step down ...

Adaptimmune Therapeutics Plc. ( (ADAP)) has released its Q3 earnings. Here is a breakdown of the information Adaptimmune Therapeutics Plc. presented to its investors. Adaptimmune Therapeutics Plc ...

Adaptimmune received FDA approval for Tecelra, with a 39% response rate in synovial sarcoma and a boxed warning for cytokine release syndrome. The U.S. population eligible for Tecelra is small ...

Cell therapies first reached patients as treatments for blood cancers. Adaptimmune Therapeutics’ work in this therapeutic modality has culminated in an FDA nod in synovial sarcoma, a regulatory ...

PHILADELPHIA & OXFORD, England, August 02, 2024--(BUSINESS WIRE)--Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy ...

Adaptimmune has won accelerated FDA approval for Tecelra (afami-cel), a treatment for metastatic or unresectable synovial sarcoma. Tecelra’s approval comes with several firsts. It’s the first ...

"This is a watershed day for Adaptimmune, for the cell therapy field and most importantly for the sarcoma community," CEO Adrian Rawcliffe said. Adaptimmune has secured Food and Drug ...

Adaptimmune (NASDAQ:ADAP) said that it has completed its planned merger with fellow T-cell therapy developer TCR2 (TCRR). The immunology companies announced the merger in March. After the closing ...

Adaptimmune and TCR2 Therapeutics, two clinical-stage biotechs that have recently cut staff to conserve capital, are coming together in a deal that aligns their cell therapy strategies. The ...

Adaptimmune Therapeutics plc (NASDAQ: ADAP) is merging with TCR² Therapeutics Inc (NASDAQ: TCRR) in an all-stock deal to create a cell therapy company focused on treating solid tumors.

At the beginning of August, preparations for Adaptimmune’s allogeneic MAGE-A4 program seemed to be near the finish line, with the company’s UK manufacturing facility almost done. The plan at ...